Search

everythinglearnresearchcommunity

for

Search:↓

Ixekizumab is safe for long-term use with low rates of major heart-related events.

Ritlecitinib helps reduce inflammation and promote hair regrowth in alopecia areata, especially in patchy-type cases.

Ritlecitinib effectively maintains hair regrowth in alopecia areata patients.

Thalidomide works best for skin lupus not helped by antimalarials, but has many side effects; other treatments are less effective, especially if patients also have systemic lupus.

In 2017, pediatric dermatology advanced with new treatments and insights into various skin conditions in children.

Expanding regulatory T cells may help treat alopecia areata by reducing harmful immune cells.

Certain cancer drugs can cause skin issues like rashes and itching.

New oral treatments for adult hair loss show promise, especially JAK inhibitors, with mild side effects.

Tofacitinib may be safe for COVID-19 patients with alopecia without worsening symptoms, based on two cases.

Biosimilars lower costs but don't significantly improve access.

Rituximab leads to longer remission and fewer side effects than cyclophosphamide.

Deuruxolitinib significantly helps regrow scalp hair in adults with moderate to severe alopecia areata.

Topical ruxolitinib quickly improves non-segmental vitiligo.

Canakinumab's effect on COVID-19 outcomes is unclear.

The combination of high-dose toremifene and capecitabine was effective for advanced recurrent breast cancer.

Combining platelet-rich plasma injections and gel may effectively treat morphea, improving skin elasticity and reducing pain.

Biologics and targeted therapies could improve treatment for children with certain chronic skin conditions.

Oral JAK inhibitors effectively treat alopecia areata and are generally well-tolerated.

Early recognition and treatment of LPP can prevent hair loss and improve quality of life.

Dabrafenib was effective and well tolerated in treating thyroid cancer with a specific mutation.

Janus kinase inhibitors are promising treatments for autoimmune skin diseases like eczema and psoriasis.

JAK inhibitors like baricitinib are a new FDA-approved treatment for alopecia areata, but safety data is incomplete.

Vismodegib effectively treats advanced basal cell carcinoma but requires careful management of serious side effects.

Ritlecitinib shows promise for treating alopecia areata, especially with early and extended treatment.

JAK inhibitors may help treat Alopecia Areata but need careful monitoring due to side effects.

Mycophenolate mofetil was effective for most patients in treating scarring hair loss, but some had side effects.

Combining low-level laser therapy with topical corticosteroids effectively improved Lichen Planopilaris symptoms.

Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.